Mercado mundial de tratamiento de la leucemia mieloide: tendencias de la industria y pronóstico hasta 2030

Análisis y tamaño del mercado de tratamiento de la leucemia mieloide

El tratamiento de la leucemia mieloide (LMA) está surgiendo constantemente para hacer frente al aumento de casos de cáncer de sangre. Entre los diversos tipos de leucemia, la leucemia linfoblástica aguda (LLA) se observa a menudo en niños y adultos jóvenes, principalmente en el grupo de edad de 2 a 5 años; sin embargo, el tratamiento de la leucemia mieloide (LMA) se observa con mayor frecuencia en adultos. Las incidencias de leucemia varían entre pacientes de diversos sexos, edades y razas y estas disparidades están asociadas principalmente con los niveles de exposición ambiental y también con factores genéticos. COVID-19 también tuvo un gran impacto en el crecimiento del mercado.

Data Bridge Market Research analiza la tasa de crecimiento del mercado de tratamiento de la leucemia mieloide en el período de pronóstico 2023-2030. Se espera que el mercado alcance los 34.300 millones de dólares en 2030, es decir, 16.000 millones de dólares en 2022, y se espera que experimente una CAGR del 10% durante el período de pronóstico de 2023 a 2030. Además de los conocimientos del mercado, como el valor de mercado, la tasa de crecimiento, los segmentos del mercado, la cobertura geográfica, los actores del mercado y el escenario del mercado, el informe de mercado seleccionado por el equipo de Data Bridge Market Research también incluye un análisis profundo de expertos, epidemiología de los pacientes, análisis de la cartera de proyectos, análisis de precios y marco regulatorio.

Alcance y segmentación del mercado de tratamiento de la leucemia mieloide

Market Definition

Myeloid leukemia is a kind of cancer of that affects blood and bone marrow. Growing diagnoses of myeloid leukemia which is caused because of exposure to carcinogens which are present everywhere, is leading to increased number of leukemia patients. Symptoms include easy bruising, breathlessness, fatigue, and bleeding. Higher risk factors such as carcinogens, bold disorders, and genetics increase the market expansion.

Myeloid Leukemia Treatment Market Dynamics

Drivers

• Huge Incidence of Myeloid Leukemia

There were around 61,780 new cases of leukemia and 22,840 mortalities in the U.S. in the year 2019. The number of myeloid leukemia treatment cases was expected at 21,450, in which adults held a major portion of the patient population. The growing incidence and increased death rate in the U.S. and other countries are building the way for increased uptake of associated therapies. It has been witnessed that 44% of acute myeloid leukaemia cases in the U.K. are in females, and 56% are in males. This factor boosts the market growth.

• Increase in Elderly Population

The elderly population is anticipated to increase the patient population worldwide, which boots the market in the forecast period 2023-2030. As per the records of the WHO, the global elderly population is anticipated to reach about 2 billion by 2050 from 617 million in 2015. The possibility of getting infected with several types of cancer also rises in this population. This factor will incease the demand of the treatment processes. This boost the market growth.

Opportunities

• Increase in usage in Hospitals

Hospitals and specialty clinics are the biggest end user of the leukemia treatment market and it is increasing because of the development of more and more hospitals. In addition to this, healthcare companies are also launching new and improved formulations of drugs for reducing the basal cell carcinoma cases. Thus, this factor will lead the market growth.

• Increased Technological Advancements

Traditional options for this diseased condition are unable to control relapse and are associated with several side-effects such as tissue damage, nausea and loss of appetite. These issues are increasing companies' focus on numerous advanced approaches such as serine-threonine protein kinases, stem cell transplant and pipeline drugs. There are numerous upcoming therapies such as immunotoxins, farnesyltransferase inhibitors, alkylating agents, FMS-like tyrosine kinase 3 inhibitors, monoclonal antibodies and multi-drug-resistant modulators that are going to contribute in the betterment of the patient condition. This creates more opportunity in the market.

Restraints/Challenges

• High Cost of Treatment

The increased expenditure of the treatment methods impede the market growth. Cost is a major factors that impacts the selection of treatment. Therefore, the high cost of myeloid leukemia treatment drugs is projected to hinder the growth of the market. Additionally, in an article published by American Society of Clinical Oncology Journal in 2020, the total annualized costs for CML was around US$ 82,054, more than those for hematologic malignancies (HEM) US$ 74,993 in the U.S. Thus, this factor hampers the market growth.

This myeloid leukemia treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the myeloid leukemia treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In 2022, the US FDA granted the company orphan drug designation for its pipeline compound OM-301 designated for the treatment of myeloid leukemia treatment (AML). It is developed by Oncolyze Inc.
• In 2021, the European Commission granted Orphan Drug Designation to SNDX-5613. It is a highly selective oral menin inhibitor for treating patients suffering from myeloid leukemia treatment (AML). It is developed by Syndax Pharmaceuticals Inc.

Global Myeloid Leukemia Treatment Market Scope

The myeloid leukemia treatment market is segmented on the basis of type, treatment type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Acute myeloid leukemia (AML)
• Chronic myeloid leukemia (CML)
• Others

Treatment Type

• Targeted Therapy
• Chemotherapy
• Cytarabine
• Anthracycline Drugs
• Alkylating Agents
• Anti-metabolites
• Tyrosine Kinase Inhibitors
• Immunotherapy
• Hormone Therapy
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Homecare
• Speciality Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

 Myeloid Leukemia Treatment Market Regional Analysis/Insights

The myeloid leukemia treatment market is analyzed and market size insights and trends are provided by type, treatment type, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the myeloid leukemia treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to have the highest market growth because of the focus of major market players on novel technology. The increasing occurrence of acute myeloid leukemia in the U.S. will lead to higher adoption of therapy for this disease, thus anticipated to boost the growth of this market in North America.

Asia-Pacific dominates the market because of the high incidence rates of leukemia. Rising R&D and product launches for myeloid leukemia are further anticipated to drive the market growth in this region. For instance, Bristol Myers Squibb received the US FDA approval for Onureg for the continued treatment of adult patients with acute myeloid leukemia who are not able to complete intensive curative therapy in 2020. ​

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Myeloid Leukemia Treatment Market Share Analysis

The myeloid leukemia treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to myeloid leukemia treatment market.

Los actores clave que operan en el mercado de tratamiento de la leucemia mieloide incluyen:

• F. Hoffmann-La Roche Ltd. (Suiza)
• Mylan NV (Estados Unidos)
• Industrias farmacéuticas Teva Ltd. (Israel)
• Sanofi (Francia)
• Pfizer Inc. (Estados Unidos)
• GSK plc (Reino Unido)
• Novartis AG (Suiza)
• Bayer AG (Alemania)
• Merck & Co., Inc. (Estados Unidos)
• Cipla Inc. (Estados Unidos)
• Abbott (Estados Unidos)
• AbbVie Inc. (Estados Unidos)
• Industrias farmacéuticas Sun Ltd. (India)
•  Aurobindo Pharma (India)
• Lupino (India)
• Hikma Pharmaceuticals PLC (Reino Unido)
• Fresenius Kabi AG (Alemania)
• Viracta Therapeutics, Inc. (Reino Unido)

SKU-52897